Karl Gaffney

Norwich, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 70 publications

Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial.

Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial.

Journal: EULAR rheumatology open

Published: August 01, 2026

Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension.

Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension.

Journal: RMD open

Published: January 26, 2026

Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies.

Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies.

Journal: RMD open

Published: June 11, 2025

Delayed diagnosis of axial spondyloarthritis: the crucial role of primary care - how you can make a difference.

Delayed diagnosis of axial spondyloarthritis: the crucial role of primary care - how you can make a difference.

Journal: The British journal of general practice : the journal of the Royal College of General Practitioners

Published: February 27, 2025

Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs.

Executive Summary: The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs.

Journal: Rheumatology (Oxford, England)

Published: January 23, 2025

What is the economic burden of delayed axial spondyloarthritis diagnosis in the UK?

What is the economic burden of delayed axial spondyloarthritis diagnosis in the UK?

Journal: Rheumatology (Oxford, England)

Published: November 21, 2024

How can ophthalmologists impact the significant delay to diagnosis in spondyloarthritis?

How can ophthalmologists impact the significant delay to diagnosis in spondyloarthritis?

Journal: Eye (London, England)

Published: November 16, 2024

Empowering people to take control of their persistent low back pain through public awareness campaigning.

Empowering people to take control of their persistent low back pain through public awareness campaigning.

Journal: Rheumatology (Oxford, England)

Published: October 25, 2024

The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs.

The 2025 British Society for Rheumatology guideline for the treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs.

Journal: Rheumatology (Oxford, England)

Published: August 31, 2024

BRITSpA at 10.

BRITSpA at 10.

Journal: Rheumatology (Oxford, England)

Published: July 19, 2024

British Axial Spondyloarthritis Inception Cohort (BAxSIC): a protocol for a multicentre real-world observational cohort study of early axial spondyloarthritis.

British Axial Spondyloarthritis Inception Cohort (BAxSIC): a protocol for a multicentre real-world observational cohort study of early axial spondyloarthritis.

Journal: Rheumatology advances in practice

Published: May 16, 2024

Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis.

Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis.

Journal: Rheumatology and therapy

Published: March 22, 2024

Showing 1-12 of 70

Last Updated: 09/26/2026